| Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (NCT05112601) | National Cancer Institute (NCI) | 2022-06-02 |
| Endometrial Cancer Recurrence in Patients Taking Metformin (NCT05192850) | WellSpan Health | 2021-12-27 |
| Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT04781088) | Floor Backes, MD | 2021-09-01 |
| Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer (NCT04906382) | Floor Backes, MD | 2021-07-01 |
| Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer (NCT04469764) | Jonsson Comprehensive Cancer Center | 2020-10-16 |
| Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers (NCT03968406) | M.D. Anderson Cancer Center | 2019-09-26 |
| Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer (NCT03914612) | National Cancer Institute (NCI) | 2019-08-22 |
| Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer (NCT03367741) | National Cancer Institute (NCI) | 2018-04-16 |
| VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer (NCT03120624) | Mayo Clinic | 2017-09-15 |
| Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer (NCT01943058) | University of Southern California | 2014-03-01 |
| Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer (NCT01652794) | Case Comprehensive Cancer Center | 2012-05-01 |
| Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer (NCT01764789) | Ohio State University Comprehensive Cancer Center | 2010-10-01 |
| Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors (NCT01198184) | National Cancer Institute (NCI) | 2010-08-01 |
| Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors (NCT01155258) | University of Southern California | 2010-06-01 |
| Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies (NCT01079832) | Case Comprehensive Cancer Center | 2009-05-01 |
| Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT00723255) | National Cancer Institute (NCI) | 2008-09-01 |
| VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT00462826) | National Cancer Institute (NCI) | 2007-11-01 |
| Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors (NCT00408655) | National Cancer Institute (NCI) | 2007-02-01 |
| Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT00301964) | National Cancer Institute (NCI) | 2006-03-01 |
| Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT00095979) | National Cancer Institute (NCI) | 2005-05-01 |
| Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT00096447) | National Cancer Institute (NCI) | 2004-11-01 |
| Biospecimen Collection in Assessing the Effect of Trametinib With or Without Uprosertib on Biomarkers in Patients With Persistent or Recurrent Endometrial Cancer Enrolled on Trial GOG02290 (NCT02093546) | M.D. Anderson Cancer Center | 2004-08-13 |
| Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial Carcinoma (NCT01689714) | Endocyte | 2003-08-01 |
| 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) (NCT00031681) | National Cancer Institute (NCI) | 2001-12-01 |
| Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors (NCT00028535) | National Cancer Institute (NCI) | 2001-11-01 |
| Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT00025467) | National Cancer Institute (NCI) | 2001-09-01 |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (NCT00004074) | National Cancer Institute (NCI) | 1999-08-01 |